INOVIO PHARMACEUTICALS, INC. annual report, FY2012

Inovio Pharmaceuticals, Inc. — 2012 Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2012, with unaudited fourth-quarter results for the three months ended December 31, 2012. Filed March 18, 2013. Inovio is a clinical-stage biotechnology company developing synthetic DNA vaccines and electroporation delivery technology; it had no approved human products and generated no product-sales revenue.

Financial performance and position

Operating losses substantially exceeded revenue, so conventional operating margins are not informative. Revenue consisted principally of grants, government contracts, license fees and collaboration payments. Revenue fell 58%, primarily because recognized NIAID contract revenue declined to $2.83 million from $7.80 million; NIAID represented 69% of 2012 revenue. R&D expense declined 10% to $17.98 million, and general and administrative expense declined 10% to $10.78 million.

Despite lower operating expenses, operating loss widened by $1.85 million and net loss attributable to Inovio increased by $4.42 million. Non-operating warrant fair-value gains decreased to $1.98 million from $8.69 million; the affiliated-company investment produced a $1.63 million gain in 2012 versus a $2.39 million loss in 2011. These valuation changes affected reported earnings and are not equivalent to operating cash generation.

Fourth-quarter 2012 revenue was $1.13 million versus $1.63 million in fourth-quarter 2011. Fourth-quarter net loss attributable to Inovio was $0.66 million versus $5.48 million. The substantially lower quarterly loss reflected, among other items, favorable warrant and affiliated-investment fair-value changes; quarterly results were volatile and should not be viewed as a measure of operating progress alone.

Cash used in operations was $22.31 million. Investing activities provided $5.28 million, chiefly reflecting investment maturities, while financing activities provided $5.33 million, primarily from the at-the-market equity program. The company reported $8.38 million of current liabilities and $2.86 million of current warrant liabilities. It reported no material long-term debt or other material long-term contractual obligations; facility and equipment operating leases totaled $1.03 million. Accumulated deficit was $229.76 million.

Material changes, business developments and outlook

• Management said cash, cash equivalents and short-term investments were expected to meet planned working-capital needs through 2014, but anticipated relying on external financing beyond that period. This is a management estimate, not a guarantee.
• In 2012 the company sold 9.34 million shares through its ATM program for $5.3 million net. After year-end it sold another 8.22 million shares for $5.6 million net and completed a March 2013 offering of shares and warrants, generating approximately $14.0 million net assuming no warrant exercise. These financings increased liquidity but diluted existing holders.
• Key programs remained at preclinical or Phase I/II stages. VGX-3100, a therapeutic HPV vaccine, was in a Phase II trial; preliminary leukemia Phase II findings described immune responses and tolerability, with the AML arm opened for enrollment. A Phase I universal H1N1 vaccine study reported cross-reactive antibody responses, and an elderly-patient study reported a 40% response rate for vaccine followed by seasonal flu vaccine versus 20% for seasonal vaccine alone. These early findings do not establish clinical efficacy.
• Management described plans for a HCV Phase I/IIa study in the second half of 2013, funded by VGX International, and a PATH/Malaria Vaccine Initiative Phase 1/2a human challenge study planned for 2014. Timing and execution remain uncertain.
• Revenue concentration and related-party exposure are notable: VGX International accounted for 14% of 2012 revenue, and the company had a 16.1% ownership interest in VGX International. VGX-related arrangements include product licensing and funding, and its subsidiary VGXI supplies DNA plasmids for research and clinical trials.
• Principal risks include recurring losses and cash burn; dependence on future financing; clinical, regulatory and manufacturing uncertainty; reliance on government contracts and a small number of collaborators; competition; intellectual-property challenges; and potential equity dilution. No legal proceedings were reported. The company reported effective disclosure controls and internal control over financial reporting, and the auditor issued unqualified opinions on the financial statements and internal controls.

Important facts for investors to verify

1. Cash runway assumptions and the cash impact of post-year-end offerings, ATM sales, clinical spending and any future capital raises.
2. NIAID contract funding, remaining performance obligations and renewal or option-year status, given that NIAID supplied 69% of 2012 revenue.
3. Clinical-trial enrollment, safety, efficacy endpoints and timelines for VGX-3100, leukemia, influenza and other lead programs; distinguish immune-response results from demonstrated patient benefit.
4. The effects of warrant remeasurement and the VGX International investment’s market valuation on reported earnings, and the potential dilution from outstanding warrants and stock options.
5. Related-party economics, including VGX International collaboration terms and plasmid-supply dependence, as well as collectability of the additional $2.0 million in OncoSec payments for which no receivable was recorded.